Disease-Modifying Drugs for Adult-Onset Rheumatoid Arthritis

Maya N Faison; Andrew M Davis; Kimberly C Trotter

doi:10.1001/jama.2023.26504

Disease-Modifying Drugs for Adult-Onset Rheumatoid Arthritis

JAMA. 2024 Mar 26;331(12):1055-1056. doi: 10.1001/jama.2023.26504.

Authors

Maya N Faison¹, Andrew M Davis¹, Kimberly C Trotter²

Affiliations

¹ Section of General Internal Medicine, University of Chicago, Chicago, Illinois.
² Section of Rheumatology, University of Chicago, Chicago, Illinois.

PMID: 38451547
DOI: 10.1001/jama.2023.26504

No abstract available

Plain language summary

This article summarizes a 2022 clinical practice guideline on the use of disease-modifying antirheumatic drugs (DMARDs) for adults with rheumatoid arthritis from the European League Against Rheumatism (EULAR).

MeSH terms

Adult
Age of Onset
Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Humans
Treatment Outcome

Substances

Antirheumatic Agents